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The proteolytic processing sites of the human immunodeficiency virus type 1 (HIV-1) Gag precursor are
cleaved in a sequential manner by the viral protease. We investigated the factors that regulate sequential
processing. When full-length Gag protein was digested with recombinant HIV-1 protease in vitro, four of the
five major processing sites in Gag were cleaved at rates that differ by as much as 400-fold. Three of these four
processing sites were cleaved independently of the others. The CA/p2 site, however, was cleaved approximately
20-fold faster when the adjacent downstream p2/NC site was blocked from cleavage or when the p2 domain of
Gag was deleted. These results suggest that the presence of a C-terminal p2 tail on processing intermediates
slows cleavage at the upstream CA/p2 site. We also found that lower pH selectively accelerated cleavage of the
CA/p2 processing site in the full-length precursor and as a peptide primarily by a sequence-based mechanism
rather than by a change in protein conformation. Deletion of the p2 domain of Gag results in released virions
that are less infectious despite the presence of the processed final products of Gag. These findings suggest that
the p2 domain of HIV-1 Gag regulates the rate of cleavage at the CA/p2 processing site during sequential
processing in vitro and in infected cells and that p2 may function in the proper assembly of virions.
Human immunodeficiency virus type 1 (HIV-1), like other
retroviruses, contains the open reading frames gag, pol, and
env. The gag and pol genes are expressed as the polyprotein
precursors Pr55 (Gag) and Prl60 (Gag/Pol). Gag and Gag/Pol
are subsequently cleaved by the viral protease (PR) to yield
mature protein products (reviewed in reference 37). Proteo-
lytic processing of the 55-kDa Gag precursor generates the
structural proteins p17 (matrix [MA]), p24 (capsid [CA]), p7
(nucleocapsid [NC]), and p6 (17, 61). Thepol gene is expressed
by a ribosomal frameshift mechanism that occurs near the
carboxyl terminus of gag (20). Proteolytic processing of the
Prl60 Gag/Pol precursor yields the viral enzymes PR (pll),
reverse transcriptase/RNase H, and integrase as well as the
Gag structural proteins (29, 60). In addition, two smaller
polypeptides with unknown function, p2 and pl, are generated
by cleavage of the Gag precursor (17). p2 in the HIV-1 HXB2
isolate (44) is 14 amino acids long and is located between CA
and NC. pl is 16 amino acids long and is located between NC
and p6.
The proteolytic processing sites in the Gag and Gag/Pol
precursors are cleaved at different rates in infected cells and in
vitro. For the Gag precursor, the different rates of cleavage at
the processing sites result in sequential processing during
which discrete intermediates appear transiently before the
final protein products (12, 34, 38, 58, 62). Three determinants
are likely to control the ordered proteolytic processing of the
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Gag precursor: (i) the sequence of the processing site, (ii) the
structural context of the processing site, and (iii) the accessi-
bility of the site to the protease. The diversity of the processing
site sequences contributes to sequential processing, because
peptides representing the known HIV-1 Gag processing sites
are cleaved at different rates (3, 6, 26, 55). However, there is
little correlation between the favorable kinetic parameters of
peptide substrates representative of the Gag sites and the
order of cleavage observed in infected cells. This suggests that
additional determinants, such as structure and accessibility,
influence sequential Gag processing (26, 52, 54, 58), although
their influence has not been defined. The importance of
ordered Gag processing in the production of a mature, infec-
tious virion is unknown. Ordered cleavage of the viral protein
precursors may be an essential component of core condensa-
tion. It is clear that processing must occur at each of the Gag
sites and to near completion to produce virions with normal
core morphology (11, 22).
The function of the small peptide domains p2 and pl of the
HIV-1 Gag precursor is also unknown. Similar domains are
found in diverse retroviruses such as mouse mammary tumor
virus, Rous sarcoma virus, bovine leukemia virus, and other
lentiviruses. In the primate lentiviruses, p2 and pl are con-
served in location in the Gag precursor, but they are poorly
conserved in sequence and length (16). In spite of the lack of
sequence conservation, the conservation of location suggests
that they have an important function in the retrovirus life cycle.
In several cases, these small peptide domains are further
cleaved by the viral PR after being released from the Gag
precursor, suggesting they function transiently during sequen-
tial processing or core formation as a component of a larger
intermediate (17, 39).
To examine the factors that regulate sequential processing
of HIV-1 Gag, the full-length Gag precursor was processed by
the viral PR in vitro. Under these conditions, Gag is processed
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in a sequential manner to yield intermediates and final prod-
ucts similar to those observed in infected cells (10, 26, 38, 58).
First, we examined whether the rate of cleavage at four
different Gag processing sites is influenced by the extent of
cleavage at the other sites. Second, the relative contributions of
processing site sequence and context in influencing the rate of
cleavage were evaluated by placement of two sites that vary
widely in their rates of cleavage in the same context in the Gag
precursor and by the hydrolysis of peptide substrates. Third, we
examined the influence of the p2 domain of Gag on sequential
processing in vitro and in infected cells. Fourth, the need for p2
in the production of infectious virions was examined.
MATERIALS AND METHODS
Plasmid constructions. The phagemid used for mutagenesis,
sequencing, and in vitro transcription of the gag gene was
pGagS. pGagS contains the gag gene from HIV-1 isolate
HXB2 (44) inserted into the vector pIBI20 (International
Biotechnologies). Features of pGagS include the gag gene
under transcriptional control of a bacteriophage T7 promoter
for the synthesis of mRNA in vitro (33) and a bacteriophage fl
origin of replication for the production of single-stranded
DNA for use in site-directed mutagenesis and DNA sequenc-
ing (63).
Design of mutagenic DNA oligonucleotides and the produc-
tion of mutations in the HIV-1 gag gene. Single-stranded
uracil-substituted pGagS used in mutagenesis was prepared by
infecting dut ung mutant Eschernchia coli CJ236/pCJ105(Cmr)
(27) containing pGagS with M13K07(b) helper phage (63). To
produce site-directed mutations in the codon for the P1 amino
acid of each of the four major processing sites in gag, 30-base
oligonucleotides complementary to single-stranded pGagS
were synthesized. During oligonucleotide synthesis, all four
deoxynucleotides were inserted at each nucleotide position of
the codon of the P1 amino acid to generate random mutations.
Synthetic 30-base oligonucleotides used for the deletion of the
p2 protein domain of Gag had the following sequences:
Ap2-composite, AAG GCAAGA GTT 1TG ATG CAG AGA
GGC AAT 3'; Ap2-fast, 5' GGA CCC GGC CAT AAG GCT
ACC ATA ATG ATG 3'; Ap2-slow, GIT ITG GCT GAA
GCA GGC AAT T`I`7 AGG AAC 3'. In vitro mutagenesis
reactions and preparation of pGagS libraries containing mu-
tations were performed as previously described (1, 27, 30, 42).
Mutations were identified by DNA sequence analysis by the
dideoxy chain termination method with modified T7 DNA
polymerase (U.S. Biochemicals) (47).
Synthesis of 5' capped mRNA and translation in vitro.
Capped mRNA was synthesized in vitro from pGagS DNA or
pGagS DNA containing selected mutations. A typical mRNA
synthesis reaction mixture contained 1.0 pug of pGagS DNA,
linearize4O with Sall, in a 20-pI reaction mixture containing 500
,M (each) UTP, CTP, and ATP; 200 ,uM GTP; 300 puM
m7G(5')pppG(5')G (Pharmacia); 40 mM Tris-HCl (pH 7.9); 6
mM MgCl2; 10 mM dithiothreitol; 2mM spermidine; 100 ,ug of
bovine serum albumin per ml; 15 U of T7 RNA polymerase;
and 40 U of RNasin ribonuclease inhibitor (Promega Corpo-
ration) (33). Transcription reaction mixtures were incubated at
37°C for 1 h, followed by a 15-min incubation with RNase-free
DNase. Synthetic mRNA (-1.0 pug) was translated in a 50-pd
reaction mixture of rabbit reticulocyte lysate (Promega Corpo-
ration) in the presence of 50 ,Ci of [35S]cysteine (1,000
Ci/mM) (DuPont NEN) for 2 h at 30°C according to the
manufacturer's instructions (Promega Corporation).
Expression and purification of the HIV-1 PR from E. coli.
Recombinant HIV-1 PR used for processing of the HIV-1 Gag
precursor and peptide substrates in vitro was expressed in E.
coli BL21(DE3) cells by inserting the gene for HIV-1 protease
with an initiating methionine into a bacteriophage T7 expres-
sion system (51). Following induction of expression, PR was
purified by a modification of the procedure of Cheng et al. (4).
Isolated inclusion bodies were solubilized in 10 ml of a buffer
containing 8 M guanidine hydrochloride, 50 mM Tris-HCl (pH
7.5), and 5 mM dithiothreitol and clarified by centrifugation.
The solubilized protein was filtered with a Centriprep-100
ultrafiltration device (Amicon) at 5,000 x g. The protein in the
filtrate was precipitated by the addition of 10 volumes of
methanol, placed at -20°C for 1 h, and collected by centrifu-
gation at 25,000 x g for 15 min. The pellet was resuspended in
3 ml of a buffer containing 8 M urea, 20 mM Tris-HCl (pH 7.5),
2 mM dithiothreitol, and 2 mM EDTA. The concentration of
protein in the 8 M urea solution was determined by using a
colorimetric assay (Bio-Rad Laboratories), and the volume of
the solution was adjusted to a concentration of less than 1
mg/ml. PR was refolded by rapid dilution into 20 volumes of
ice-cold folding buffer (20 mM sodium acetate [pH 5.5],
containing 1 mM EDTA, 2.5 mM dithiothreitol, and 10%
glycerol) (53). After refolding, any insoluble aggregated pro-
tein was removed by centrifugation at 25,000 x g for 15 min.
The refolded PR was concentrated in a Centriprep-10 filtration
device (Amicon) at 4°C, during which time the buffer was
exchanged with 3 volumes of fresh folding buffer to remove any
residual urea. Aliquots of the refolded PR were stored at
-70°C. PR obtained by this procedure was greater than 90%
pure as judged by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and (28) was stable for several
months when stored at -70°C.
In vitro assays for the proteolytic processing of Gag. Pro-
cessing of the Gag precursor in vitro was performed with 50-pl
reaction mixtures containing 5 pl of the rabbit reticulocyte
lysate translation mixture and purified recombinant PR (1.0 to
5.0 pug) in modified AMT buffer (9) (50 mM acetic acid, 50 mM
MES [morpholineethanesulfonic acid], 100 mM Tris, 150 mM
NaCl) at either pH 5.0 or pH 7.0. All reactions were performed
at 30°C. Aliquots of 5 pI were taken at various times, mixed
with 10 pI of 2x SDS-PAGE loading buffer (28), and heated to
100°C for 3 min. Products of the processing reaction were
separated by SDS-PAGE (28), fixed in 20% methanol-10%
acetic acid-5% glycerol, dried, and exposed to X-Omat AR
film (Eastman Kodak Co.). Relative quantitation of labeled
protein products was performed by densitometry analysis of
autoradiographs on a Molecular Dynamics model 300 densi-
tometer or by analysis of the radioactivity in the gel by using a
Molecular Dynamics model 400 Phosphoimager.
Calculation of the relative rates of cleavage for the process-
ing sites in Gag. The relative amount of protein represented by
bands in autoradiographs of Gag processing assays was deter-
mined by correcting for the relative amount of cysteine label in
each protein species. The amount of uncleaved substrate for an
individual site was determined as the remaining amount of the
various precursors containing the uncleaved site. This value
was represented as a percentage of the total amount of sub-
strate in the lane by dividing by the total amount of p24-
containing species. In some instances the amount of some
intermediates could not be determined because of background
radioactivity in the size range of 7 to 10 kDa that appeared on
the autoradiographs. In these cases, the indiscernible interme-
diates were not included in the calculations of total uncleaved
substrate.
Relative rates of cleavage for the individual sites in the Gag
precursor were calculated from semi-log (first-order) plots in
which the log of the percentage of the initial substrate remain-
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ing was plotted versus time. The rate of cleavage at a particular
site was estimated by the average slope of the line through time
points representing 20 to 80% cleavage. The maximum amount
of assay time utilized for the rate calculations was 1 h, during
which time the PR retained at least 80% of its initial activity as
judged by cleavage of a radiolabeled peptide substrate under
identical assay conditions. The numerical values of the rate
were then used to compare the relative rates of cleavage for
the Gag processing sites.
Construction of infectious HIV-1 clones, cell transfection,
and Western blots (immunoblots). Regions of the plasmid
pGagS containing deletions in the p2 domain of Gag were
subcloned into the plasmid pMM4, which contains an infec-
tious genomic copy of the HIV-1 HXB2 isolate (44). An
aliquot of 30 ,ug of twice-CsCl-banded plasmid DNA was
transfected into HeLa cells in 100-mm plates by CaPO4
precipitation (13, 21). At 48 h posttransfection, the medium
was collected and stored frozen for later use. The cells were
washed in phosphate-buffered saline and lysed in 300 p1 of
modified radioimmunoprecipitation assay buffer (21), with 100
,ug of AEBSF [4-(2-aminoethyl)-benzenesulfonyl fluoride hy-
drochloride] per ml (ICN Biomedicals) replacing phenylmeth-
ylsulfonyl fluoride. Insoluble debris was removed by centrifu-
gation at 15,000 x g for 10 min. For Western blot analysis, 3 to
15 p1 of extract was subjected to SDS-PAGE and transblotted
to nitrocellulose as described previously (41). Western blotting
was performed with biotinylated secondary antibody and
streptavidin-alkaline phosphatase conjugate as described pre-
viously (41) with the following modification: blots were
blocked in 0.5% gelatin in Tris-buffered saline-0.05% Tween
20 (TBS-Tw) for 1 h. Blocked blots were exposed to either
anti-HIV-1 matrix monoclonal antibody (Cellular Products,
Inc.) or anti-HIV-1 capsid monoclonal antibody (DuPont) at a
1:1,000 dilution in TBS-Tw, or were exposed to anti-HIV-1 p6
monoclonal antibody (61) at a 1:30 dilution in TBS-Tw.
Determination of the production and relative infectivity of
wild-type and mutated virions. The presence of virus particles
released into the medium was determined by the sedimenta-
tion of particles through a cushion of 15% sucrose (100,000 x
g, 90 min) (5, 64). The presence of virus particles in the
medium and pellet was confirmed with a reverse transcriptase
assay (36) and a p24 CA antigen enzyme-linked immunosor-
bent assay (ELISA) (DuPont). In addition, the presence of the
processed Gag proteins MA, CA, and p6 in the pelleted virions
was confirmed by Western blotting.
The ability of released virus to infect cells was judged by two
methods. First, virus-containing medium was used to infect
CD4-LTR/3-gal indicator cells (Magi cells) as described pre-
viously (24). Two days later, infected cells were detected by
colorimetric assay for evidence of infection. The relative
infectivity of the released virus particles was estimated by
comparing the number of infectious units as measured on
CD4-LTR/3-gal cells with the amount of virion-associated p24
CA antigen in the medium as determined by ELISA. In the
second assay, we determined the ability of released virus
particles to productively infect CEM cells. A sample of 2 x 106
cells was exposed to 500 RI of virus-containing medium col-
lected 48 h posttransfection as described previously (21). The
cells were observed daily for the presence of cytopathic effect.
After 3 weeks, all cultures were assayed for the presence of p24
CA antigen in the medium by using an ELISA.
Determination of the PR activity on peptide substrates. PR
activity was assayed in AMT buffer at 37°C either with a
radiometric assay or by analysis of reaction products by fast
protein liquid chromatography (FPLC). The kinetic parame-
ters of Km and kcat (the Michaelis-Menten parameter for
catalytic-site activity) values were obtained by fitting data to
the Michaelis-Menten equation with a basic program employ-
ing the nonlinear regression routine of Duggleby (8), which
was kindly provided by Dexter Northrop, University of Wis-
consin.
The radiometric assay employed the substrate [3H]Ac-
SQNYPIVR in a modification of an assay described by Ido et
al. (19). Reactions were performed in 25-,u volumes and were
linear over the 30-min period of incubation, with less than 10%
substrate cleavage. The assays were terminated by the addition
of Dowex X-50W-X4 (5% [wt/vol]) in 0.1 M acetic acid. The
acetylated cleavage product in the supernatant was quantitated
by liquid scintillation counting.
Reactions with the peptide KARVLAEAMSNph were per-
formed in 100 RI (pH 7.0) or 400 RI (pH 5.0) of AMT buffer
and were terminated after 30 min with trifluoroacetic acid to a
final concentration of 1%. The cleavage product AEAMSNph
was separated from the uncleaved substrate by FPLC and
quantitated spectrophotometrically. The kinetic measurements
for both peptide substrates were determined at concentrations
that spanned the derived Km values except for the substrate
representative of the MA/CA processing site, for which maxi-
mum solubility was obtained at 19 mM at pH 7.
RESULTS
Cleavage of the Gag precursor in vitro: observed interme-
diates and final products. To study the determinants that
regulate sequential processing of the HIV-1 Gag precursor, we
employed an assay in which labeled Gag precursor is processed
sequentially in vitro after the addition of HIV-1 PR (10, 26, 38,
58). The intermediates and final products that arise during
sequential processing of Gag with this assay correlate well with
processing events observed in infected cells (12, 34, 38, 58, 62).
The assay has advantages in that differences in the rates of
cleavage at the Gag processing sites can be more accurately
estimated than those in infected cells. Previously published
data describing sequential processing of the HIV-1 precursor
in vitro (10, 26, 38, 58), in combination with the mutagenesis of
processing sites (see below), allowed the composition of pro-
cessing intermediates and final products to be determined.
Translation of synthetic gag mRNA in a rabbit reticulocyte
lysate system yielded labeled full-length Gag precursor Pr55 as
the predominant protein product (Fig. 1, lanes 0 min, and Fig.
2A), which was rapidly processed at neutral pH upon addition
of recombinant HIV-1 PR. Initially, Gag was cleaved at the
p2/NC cleavage site to yield the MA-CA-p2 intermediate
(designated p39a) and the p15 intermediate (NC-pl-p6) pre-
viously described by Veronese et al. (61) (Fig. 1, lanes 1, and
Fig. 2B). The p15 intermediate was cleaved at the pl/p6 site
approximately ninefold more slowly than the initial cleavage to
yield a 7-kDa product (p7) consisting of NC-pl. The p39a
intermediate was later cleaved at the MA/CA site at an
approximately 14-fold slower rate to yield the MA final
product, pl7, and a p25 intermediate consisting of CA-p2. In
the fourth cleavage observed, the CA/p2 site of the p25
intermediate was cleaved at an estimated 400-fold slower rate
than the initial cleavage at p2/NC. In some experiments, we
also observed slow processing of the NC-pl intermediate to
yield the unidentified product p7*. However, the apparent size
of p7* during SDS-PAGE varied with the pH of the cleavage
assay, suggesting altered processing with changes in pH (40).
Thus, the order of cleavages for the four processing sites at
neutral pH is p2/NC > pl/p6 -MA/CA > CA/p2, with the two
sites flanking the p2 domain differing roughly 400-fold in their
rate of cleavage. This order is in agreement with data from
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FIG. 1. Sequential processing in vitro of the HIV-1 Gag precursor and of Gag with P1 amino acid substitutions. Assays were performed with
labeled Gag as described in Materials and Methods at pH 7. Aliquots were collected from the processing reaction mixtures at the times indicated
and subjected to SDS-PAGE with a 17% acrylamide gel (28). Molecular mass markers and the observed intermediates and final products for
wild-type Gag (lanes 1) are shown. Lanes containing aliquots from processing reactions of Gag with P1 substitutions are as follows: lanes 2, P1 Leu
at the MA/CA site; lanes 3, P1 Ile at the MA/CA site; lanes 4, P1 Ile at the CA/p2 site; lanes 5, P1 Leu at the p2/NC site; lanes 6, P1 Ile at the
p2/NC site; lanes 7, P1 Ile at the pl/p6 site. The dark area that extends from 7 to 10 kDa on autoradiographs of SDS-PAGE gels was found to
be an artifact of translation in vitro when [35S]Cys is used as a label because it was also present in translations without added mRNA (not shown).
During SDS-PAGE, the p15 intermediate was observed to migrate more slowly than p17 MIA. This altered migration was previously observed for
these products during processing in vitro (38) and has also been observed for viral proteins (40). The HIV-1 p6 protein (61) was not visible in the
autoradiographs of SDS-PAGE gels because it contained no labeled residues. The amino acid sequence of the HIV-1 PR was as reported
previously (44).
previous reports (26, 38, 58), although the differences in rate
observed here are greater than earlier estimates (10, 58).
Cleavage of the processing sites in the Gag precursor are
not necessarily independent events. To determine the inde-
pendence of the cleavages during sequential processing, we
constructed four Gag precursors containing mutations de-
signed to prevent processing at the MA/CA, CA/p2, p2/NC, or
pl/p6 site. The effect of the blocking mutation on the cleavage
of the other three sites was monitored. Previous reports
indicated that conservative substitution of the P3-branched
amino acid Ile at the P1 position of a site prevents cleavage of
a Pol processing site in E. coli (42) (the P1 residue is the first
amino acid located upstream of the scissile bond in the
substrate [48]) and of peptides representative of cleavage sites
(2, 25, 45, 57). As a control, the similar amino acid Leu was
also substituted for the P1 amino acid at either the MA/CA or
p2/NC site. Leu is common to the P1 position of processing
sites (42, 43) and is the P1 amino acid of the CA/p2 processing
site (17). As shown in Fig. 1 (lanes 3, 4, 6, and 7), substitution
of the P1 residue with Ile prevented cleavage at each of the
four sites as judged by the absence of one or more of the final
processed products. Preventing cleavage at a site also altered
the composition or time of appearance of intermediate prod-
ucts during sequential processing (Fig. 1 and 2C). P1 Leu
substitutions at the MA/CA and p2/NC sites caused these sites
to be cleaved at rates estimated to be 15- and 2-fold slower,
respectively. The P1 Leu substitutions also resulted in the
transient appearance of the same novel intermediates observed
with a P1 Ile substitution (Fig. 1, lanes 2 and 5), although with
a P1 Leu substitution, these intermediates were eventually
cleaved. Thus, the substitution of a P1 Ile blocked cleavage at
all four Gag processing sites, while a P1 Leu substitution
reduced the rate of cleavage by an amount that was dependent
on the site.
With one exception, cleavage of the four Gag sites occurred
independently (Fig. 3). The exception occurred for the site
upstream of the p2 domain. When initial cleavage at the p2/NC
site was blocked, the upstream CA/p2 site was cleaved approx-
imately 20-fold faster, without affecting the rate of cleavage at
the other sites. The rate of cleavage at the CA/p2 site was not
influenced by blocking the other sites in Gag. Accelerated
cleavage of the CA/p2 site was not strictly dependent on the P1
Ile substitution at the p2/NC site, because other mutations that
blocked cleavage at the p2/NC site also accelerated cleavage at
the CAIp2 site (40). These data suggest that sequential pro-
cessing is regulated, at least in part, by an interaction between
the two sites flanking the p2 domain. Initial cleavage at the
downstream site down-regulates the rate of cleavage at the
upstream site. This negative regulation of cleavage at the
CA/p2 site contributes significantly to the 400-fold difference
in the cleavage rates at these two adjacent sites.
The p2 domain of Gag negatively regulates the rate at which
the CA/p2 site is cleaved in vitro. To confirm that the p2
domain of Gag was responsible for the negative regulation of
cleavage of the CA/p2 site, the p2 domain was deleted from the
Gag precursor. The deletion (Ap2-slow) removed the p2
domain and the seven-amino-acid recognition sequence (3, 6,
35, 56) of the p2/NC cleavage site, leaving intact the sequence
of the CA/p2 cleavage site (Fig. 4A). Without the presence of
p2, the CA/p2 site in Ap2-slow Gag was accelerated by an
amount similar to that observed earlier when the downstream
p2/NC site was blocked from cleavage (M3771) (Fig. 4B). This
suggests that p2 and not the CA/p2 cleavage site sequence is
largely responsible for the slow rate of cleavage of the CAIp2
site during sequential processing. In addition, p2 must have a
carboxyl terminus freed by prior cleavage of the downstream
site to exert the negative effect on cleavage at the CA/p2 site.
To examine whether the p2 domain influences the rate of
cleavage of the downstream p2/NC site, an additional p2
deletion (Ap2-ast) was constructed that retained the faster
p2/NC cleavage site sequence (Fig. 4A). The deletion mutants
Ap2-slow and Ap2-ast effectively placed the sequence of the
sites flanking p2 in the same context in the Gag precursor.
Compared with wild-type Gag, the p2/NC site in Ap2-fast was
cleaved roughly threefold slower. Thus, without the influence
of the p2 domain, the difference in the rates of cleavage at the
two processing site sequences was reduced from approximately
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FIG. 2. HIV-1 gag vector and Gag processing intermediates and
products. (A) The phagemid pGagS contains the HIV-1 gag gene
under transcriptional control of the bacteriophage T7 promoter, which
is utilized to produce labeled Gag precursor by transcription and
translation in vitro. The locations of the five major processing sites in
the Gag precursor, as identified by sequencing of virion proteins, are
denoted by arrows (17). The amino acid sequences (P4 to P3') of the
four major processing sites evaluated in this study are shown in the
single-letter code with the position of the scissile bond denoted by a
slash. The numbers above the sites indicate differences in the esti-
mated rate of cleavage by HIV-1 PR in vitro at pH 7, with the rate of
initial cleavage at the p2/NC site set to a value of 1. (B) Schematic of
processing intermediates and final products observed during sequen-
tial processing of the wild-type Gag precursor in vitro at pH 7. The
intermediates and final products are shown in decreasing apparent
molecular mass as determined by SDS-PAGE (28). (C) Schematic of
novel processing intermediates and final products observed during
sequential processing in vitro when processing sites were inhibited by
a P1 Ile substitution during in vitro processing reactions at pH 7. Some
of the same intermediates were observed when the assays were
performed at pH 5 (see Results). The processing sites containing an
inhibitory P1 Ile substitution are indicated by X. The substituted amino
acid and its position within Gag translated from the sequence of the
HXB2 HIV-1 isolate are indicated to the right (44).
the p2 domain in the Gag precursor functions to maximize the
difference in the cleavage rate between the CA/p2 and p2/NC
sites. A third p2 deletion, Ap2-composite, created a composite
CA/NC site with a P1 Leu/P1' Met combination not normally
found in HIV-1 cleavage sites (31). This composite site was
cleaved at a rate midway between the sites flanking p2 (data
not shown).
Lower pH accelerates cleavage of the CA/p2 site by a
sequence-based mechanism. Assay conditions with lower pH
have been successfully used to study the accessibility of pro-
teinase cleavage sites in native proteins (65). A previous report
showed that lower pH alters the accessibility of a potential
cleavage site in lactate dehydrogenase to permit cleavage by
the HIV-1 PR (54). In addition most kinetic analyses of HIV-1
PR with peptide substrates are performed at the kinetic
optimum, which is approximately pH 5 (3, 18, 46). We used this
approach to test the possibility that protein conformation was
involved in regulating the ordered cleavage of Gag.
Lowering the pH of the in vitro assay to pH 5 affected the
cleavage of the four Gag sites differently. The CA/p2 site was
affected the most, being cleaved roughly 20-fold faster than at
pH 7. The faster cleavage at the CA/p2 site resulted in an
additional 39-kDa intermediate (designated p39b), consisting
of MA-CA, that migrated slightly faster than the p39a inter-
mediate during SDS-PAGE (Fig. 5A, lane 1). Faster cleavage
at the CA/p2 site also accelerated removal of p2 from the p25
CA-p2 intermediate (Fig. 5A). Cleavage at the MA/CA and
p2/NC processing sites was not significantly affected, while the
pl/p6 site was cleaved approximately threefold faster at lower
pH. Thus, lower pH selectively accelerated cleavage of the
CA/p2 site and reduced the differences in the rates of cleavage
of the Gag sites to roughly 20-fold from 400-fold.
Selective acceleration of the cleavage of the CA/p2 site at
lower pH apparently occurred independently of the presence
of the p2 domain. We observed further acceleration in the rate
of cleavage of the CA/p2 site in Gag, in which the negative
effects of the p2 domain were removed by mutagenesis
(M3771, Ap2-slow; Fig. 5B). The additive effects of lower pH
and removing the down-regulating effects of a p2 tail resulted
in over 100-fold enhancement of cleavage at the CA/p2 site in
Gag with the M3771 mutation and a 43-fold enhancement in
Gag with the Ap2-slow mutation. These results suggest that the
combination of physiological pH and negative regulation by
the p2 domain is largely responsible for the slow rate of
cleavage of the CA/p2 site in the virion.
Acceleration of the CA/p2 site at lower pH apparently is
dependent on a component of the processing site sequence
(KARVL/AEA). The sequences of the p2/NC site (ATIM/
MQR) (Ap2-fast) and the CA/NC composite site sequence
(KARVL/MQR) (Ap2-composite) when placed in the same
context as the Ap2-slow mutation were not accelerated at pH
5 (data not shown). These results suggest the P1' to P3'
residues of the CA/p2 site are responsible for accelerated
cleavage at pH 5.
To confirm that a sequence-based mechanism is responsible
for accelerated cleavage of the CA/p2 site at lower pH,
peptides representative of the MA/CA and CA/p2 processing
sites were digested with HIV-1 PR at pH 5 and 7 under the
buffer conditions identical to those utilized for the hydrolysis of
the full-length Gag precursor. The kinetic parameters of Km
and kcat for hydrolysis of the two peptides are shown in Table
1. These data indicate that the Km for both peptides was lower
at pH 5 than at pH 7, in agreement with previously published
reports that the Km of hydrolysis of a peptide substrate by
HIV-1 PR decreases with pH (7, 18, 19, 46). The change in the
kcat/Km value with the drop in pH closely approximated the
difference in the rate of cleavage between these two sites
observed with the Gag precursor. The peptide representative
of the CA/p2 site showed a 25-fold improvement, while the
peptide representative of the MA/CA site had a 3-fold im-
provement. These results are consistent with the interpretation
that a sequence-based mechanism is responsible for accelera-
tion of the CA/p2 site at lower pH, rather than a change in
conformation or accessibility.
The p2 domain of Gag negatively regulates cleavage of the
CA/p2 site during virion formation. We examined whether the
presence of the p2 domain negatively regulates the rate at
which the CA/p2 site is cleaved in infected cells. To accomplish
this, we transferred the Ap2-slow deletion (Fig. 4A) into an
infectious molecular clone of the viral genome (44), trans-
fected the clone containing the mutation into cells, and
monitored cleavage of the CA/p2 site during sequential pro-
cessing. As a control, the Ap2-composite mutation (Fig. 4A),
which removes the p2 domain in its entirety without disrupting
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FIG. 3. The independence of cleavage at the four processing sites during sequential processing. Each plot shows the percentage of initial
uncleaved substrate remaining as a function of time for cleavage at one of the four processing sites in the wild-type Gag precursor (0) and Gag
in precursors containing an Ile substitution at the P1 amino acid at one of the four processing sites: MA/CA, *; CA/p2, 0; p2/NC, A; and pl/p6,
*. A P1 Ile substitution at each of the four sites prevented cleavage at that site as judged by the absence of the normal product. The apparent
cleavage of substrate at the p2/NC site and pl/p6 sites containing P1 Ile substitutions is attributed to difficulties with the densitometric estimation
of some intermediates comigrating with the unincorporated labeled amino acid on autoradiographs of processing reactions or the presence of
secondary cleavage sites in some Gag intermediates (17).
the primary amino acid sequence of the CA or NC protein, was
also transferred into an infectious viral clone. Two days
posttransfection, the processing intermediates were examined
by Western blotting. As shown in Fig. 6, the slow rate of
cleavage at the CA/p2 site in wild-type Gag resulted in the
p39b intermediate (MA/CA) being a minor species during
sequential processing. In Ap2-slow Gag, however, accelerated
cleavage of the CA/p2 site was demonstrated by increased
amounts of the p39b intermediate. The amount of the p39b
intermediate indicates that the rate of cleavage at the CA/p2 in
Ap2-slow Gag is comparable to the rates of cleavage at the
MA/CA site (to give p40-Ap2) and at the-pl/p6 site (to give
p49-Ap2 and p33). Deletion of the p2 domain, in both the
Ap2-slow and Ap2-composite genomes, had no effect on the
formation of the final processed products p17-MA, p24-CA,
and p6 compared with the wild type, nor did the deletions have
any effect on accumulation of the p15 (NC-pl-p6) intermedi-
ate. As expected, the singularly cleaved intermediates corre-
sponding to p49 (MA-CA-p2-NC-pl) and p40 (CA-p2-NC-pl-
p6) migrated faster in SDS-PAGE when the p2 domain was
deleted from Gag. These results indicate that the presence of
the p2 tail on processing intermediates negatively regulates the
rate at which the CA/p2 site is cleaved during sequential
processing in cells.
The p2 domain of Gag is important for the production of
infectious virions. To determine whether the p2 domain is
necessary for the budding of virions, medium from cells
transfected with the wild-type genome or genomes containing
either the Ap2-slow or Ap2-composite deletion mutation was
examined for the presence of virus particles by sedimentation
through a sucrose cushion (5, 64). As a control for the
pelleting, stocks of avian leukosis virus and murine leukemia
virus were also pelleted under the same conditions as HIV-1.
The presence of pelleted HIV-1 virions was determined by
reverse transcriptase assay, p24 CA ELISA, and Western blot
analysis. As shown in Table 2, deletion of the p2 coding
domain had little effect on the release of virions into the
medium compared with the wild type by reverse transcriptase
assay or p24 CA antigen capture (40). Western blot analysis of
the pelleted virions showed predominately processed Gag
proteins (MA, p24 CA, and p6) in the wild-type and p2-deleted
virions (40).
Next, we examined whether virions deleted in p2 were
infectious by two different methods. First, p2-deleted virions
were tested for their ability to productively infect CEM cells.
As shown in Table 2, virions containing either the Ap2-slow or
Ap2-composite deletion of the p2 domain were not able to
maintain a stable infection in CEM cells through 3 weeks of
culture as measured by the presence of cytopathic effect or
supernatant p24 capsid antigen. Second, we examined the
ability of virus to infect cells by the multinuclear activation of
a galactosidase indicator (MAGI) assay (24). The MAGI assay
measures infection of a cell by the induction of an endogenous
,-galactosidase gene under transcriptional control of the
HIV-1 long terminal repeat and thus does not require viral
spread through the culture. The titration of infectious particles
by the MAGI assay, in combination with quantitation of the
virion by reverse transcriptase activity, allowed the relative
infectivity of virus particles to be estimated. As shown in Table
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FIG. 4. The effect of the p2 domain on Gag cleavage in vitro. (A)
The amino acid sequence of the p2 domain of wild-type Gag is shown
in the single-letter code. The seven-amino-acid recognition sequences
of the CA/p2 and p2/NC processing sites are shown in boldface type,
with the slash representing the scissile bond. The p2 domain was
removed in three different deletions that retained either the seven-
amino-acid sequence (3, 6, 56) of the p2/NC site (Ap2-fast) or the
CA/p2 site (Ap2-slow) or created a composite CA/NC processing site
(Ap2-composite). (B) Accelerated cleavage of the CA/p2 site by
preventing the formation of the p2 tail. The percentage of initial
substrate containing an uncleaved CA/p2 site with time is shown for
two mutations that prevent formation of the p2 tail during sequential
processing reactions in vitro. The M3771 mutation blocked cleavage of
the downstream p2/NC site by the substitution of a P1 Ile, while the
Ap2-slow mutation deleted both the p2 domain and the p2/NC site
from the Gag precursor. For comparison, cleavage of the wild-type
precursor (W.T.) over time is also shown.
compared with the wild type, the Ap2-composite and the
Ap2-slow deletions resulted in particles at least 20-fold less
infectious. In some experiments, the Ap2-slow-deleted virus
was less infectious than the Ap2-composite-deleted virus,
possibly because this deletion resulted in the substitution of the
first three amino acids of NC (Fig. 4A).
DISCUSSION
In this study, we have explored the mechanisms that regulate
sequential processing of the HIV-1 Gag precursor. Our initial
strategy was to determine if cleavage at one site was dependent
on cleavage at another site. We used an approach in which
each of four major processing sites was selectively blocked
from cleavage by substitution of the P1 residue with Ile. A P1
Ile has been shown to block cleavage of peptide and Pol
substrates by the HIV-1 PR (2, 42, 45, 57) and by the avian
myeloblastosis virus PRs (25), possibly because of an unfavor-
able interaction of the ,-branched side chain with the catalytic
aspartate (57). We found that cleavage at three of the four sites
examined occurred independently of cleavage at the other sites
(Fig. 3). However, the CA/p2 site was accelerated 20-fold when
the p2/NC site was blocked. Tritch et al. (58) have previously
noted that replacement of the p2/NC cleavage site with the


























FIG. 5. Sequential processing of the HIV-1 Gag precursor in vitro
at either pH 5 or pH 7. (A) Processing of labeled Gag precursor was
performed as described in Materials and Methods. Aliquots were
collected from the processing reaction mixtures at the times indicated.
Molecular mass markers and the composition of observed intermedi-
ates and final products are shown. The estimated difference in the rates
of cleavage at the two sites flanking the p2 domain was estimated to be
approximately 400-fold at pH 7 and 15-fold at pH 5. (B) Accelerating
effects of lower pH on the rate of cleavage at the CA/p2 processing site
in wild-type Gag and Gag containing mutations preventing p2 tail
formation on processing intermediates. The percentage of initial
uncleaved substrate remaining with an uncleaved CA/p2 site is plotted
as a function of time during sequential processing reactions. The
estimated relative rates of cleavage for the CA/p2 site are also shown
for a single experiment, with the rate of cleavage in the wild-type
precursor set to a value of 1. *, cleavage of the wild-type Gag
precursor at pH 7; *, Gag containing a P1 Ile substitution at p2/NC
(M3771) at pH 7; A, Gag with both the p2 domain and the p2/NC
processing site deleted (Ap2-slow) at pH 7. The corresponding open
symbols indicate reactions performed at pH 5.
at CAIp2, although the magnitude of the effect was not
determined.
p2 as a regulator of sequential processing. Either mutation
that blocks initial cleavage at the p2/NC site or a deletion that
removes the p2 domain resulted in accelerated cleavage at the
CA/p2 site (Fig. 4B). Thus, it is the presence of the p2 tail on
processing intermediates (p39a and p25) that negatively regu-
lates the rate of cleavage. These data support a model in which
the p2 domain functions to regulate sequential processing by
slowing cleavage at the CA/p2 site. This regulation, in turn,
contributes significantly to the approximately 400-fold differ-
.7,_W.
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TABLE 1. Kinetic parameters for the hydrolysis of peptides
representative of the MA/CA and CA/p2 processing
sites by HIV-1 PR at pH 5 and 7
Site Sequence pH Km (mM) kcata kcatlKm
MA/CA AcSQNY/PIVR 5.0 5.3 ± 1.4 20 ± 3 3.8
7.0 87 ± 16k 114 ± 18 1.3
CA/p2 KARVL/AEAMSNph 5.0 0.11 ± 0.02 2.0 ± 0.1 18.2
7.0 3.14 ± 0.46 2.2 ± 0.2 0.7
a Number of substrate molecules transformed per second per molecule of
enzyme.
b The maximum substrate concentration used in determination of this value
was 19 mM.
ence in the rates of cleavage of the Gag sites in vitro. The role
of the p2 domain as a negative regulator of the cleavage of the
CA/p2 site in infected cells was also confirmed. This was
evident by a significant increase in the formation of the
MA/CA intermediate when the p2 domain was removed (Fig.
1, 4B, and 6).
It is not known whether a particular sequence or length of p2
is necessary for the regulation of cleavage at the CA/p2 site. p2
is poorly conserved in sequence between the primate lentivi-
ruses (16) and can be variable in sequence and composition in
different HIV-1 isolates (31). Cleavage sites embedded within
the context of a large protein may simply be cleaved more
efficiently by the HIV-1 PR than sites near the end of the
protein precursor. We cannot exclude, however, that p2 may
also perform a function other than that described here.
Processing intermediates with small peptide domains may have
a transient function during virion maturation. Such an example
is seen with the bovine leukemia virus matrix protein, in which
a carboxy-terminal extension is necessary for the binding of
viral RNA (23). Nevertheless, p2 does function to regulate the
rate at which the CA/p2 site is cleaved during sequential
processing of HIV-1 Gag, and its presence is important for the
production of fully infectious virus (Table 2). A report by
Craven et al. (5) has also demonstrated the importance of the
anti-p24 CA ant
TABLE 2. Effect of deletion of the p2 domain on production
of infectious HIV-1 particles
%ofrion- Relative % of
associated RT infectivity GEM 11l GEM cellVirus aciiyin': (wild type = cyoati P24 GA an-
construct acti i y cytopathic tigen pro-
ductionc
Expt 1 Expt 2 Expt 1 Expt 2
Mock 0 0 0 0 - -
HIV-1 wild type 25 27 100 100 + +
Ap2-composite 16 29 3 1
Ap2-slow 15 21 2 <1 - -
a Percentage of medium-associated reverse transcriptase (RT) activity able to
be pelleted by centrifugation through a 15% sucrose cushion. As a control, viral
stocks of murine leukemia virus and avian leukosis virus were pelleted under the
same conditions, with percentages of HIV-1 virion reverse transcriptase activity
of 65 and 87%, respectively.
b The number of infectious particles by MAGI assay and pelletable reverse
transcriptase activity.
c CEM cells were infected with 500 ,ul of medium collected 48 h posttransfec-
tion and monitored for cytopathic effect and p24 CA antigen production over a
3-week period.
spacer peptide located between CA and NC of Rous sarcoma
virus Gag to produce infectious virions.
The effect of pH on cleavage of the Gag sites. Processing
reactions were performed at pH 5 to gain insights into the
mechanism by which the p2 tail slows the rate of cleavage at
the CA/p2 site. Lower pH makes a potential processing site
sequence in native lactate dehydrogenase more accessible to
cleavage by HIV-1 PR (54). Thus, processing reactions per-
formed at lower pH may serve as a probe for conformationally
sensitive areas. Varying the pH of in vitro assays has also been
used as a probe for potential electrostatic interactions between
proteinases and substrate (14, 18, 49). We found that the
CA/p2 site was selectively accelerated by the drop from neutral
pH relative to the other Gag sites. Accelerated cleavage at the
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FIG. 6. Analysis of processing intermediates observed in cells transfected with the wild-type (W.T.) HIV-1 genome or genomes deleted in the
p2 domain. Samples were analyzed by Western blotting with the indicated antibodies after SDS-PAGE on a 17% acrylamide gel. The positions
of molecular mass markers are shown on the right. The positions of the Gag precursor, the composition of processing intermediates, and the final
products are shown on the left of each panel. The deletion mutants used were Ap2-slow and Ap2-composite.
J. VIROL.
SEQUENTIAL PROTEOLYTIC PROCESSING OF HIV-1 Gag 8025
of the p2 tail (Fig. SB), suggesting sequence-based electrostatic
influences rather than changes in accessibility or conformation.
The influence of pH on the. cleavage of the CA/p2 site was
confirmed by the hydrdlysis of a peptide substrate as well
(Table 1). There is general agreement that the rate of hydro-
lysis of peptide substrates by HIV-1 PR increases at lower pH
near pH 5 (3, 18, 19, 46). Previously published reports have
noted that the sequence of the CA/p2 site is one of the best
HIV-1 processing sites when assayed as a peptide at low pH
(45, 55). Under conditions of lower pH and with a mutation
preventing the formation of the p2 tail (M3771), we observed
that the CA/p2 site in the native Gag precursor was cleaved
faster than the MA/CA site (40). Evidently, in the virion, the
combination of neutral pH and negative regulation by the p2
domain slows cleavage of the CA/p2 site so that it is one of the
slowest Gag sites.
Dilanni et al. (7) and Richards et al. (45) also noted an
increase in Km for the hydrolysis of a peptide representative of
the CAIp2 site at higher pH, although the exact magnitude of
the increase at neutral pH was not determined. Our results
suggest one or more of the residues in the P1' to P3' position
of the CA/p2 site are responsible for the sensitivity to varia-
tions in pH. A P2' Glu among the HIV-1 cleavage sites is
unique to the CA/p2 site, and a P2' Glu has been implicated in
favorable recognition of heterologous cleavage sites in protein
precursors (43, 52, 54), peptide substrates (15, 43), and sub-
strate-based inhibitors by PR (32, 59). However, most of these
studies have been based on experimental data collected near
pH 5. Protonation of the P2' Glu at lower pH may allow a
more favorable association with the S2' subsite of PR. In that
case, a P2' Glu in a substrate may be less favorable at
physiological pH.
The influence of sequence and context on determining the
rate of cleavage at a processing site. This report emphasizes
the importance of context in regulating the rate of cleavage at
a processing site. When the two sites flanking the p2 domain
are placed in identical context in the native Gag precursor, the
difference in the rates of cleavage was reduced from 400-fold to
15-fold (not shown). In addition, the change of context had a
bidirectional effect on the rate of cleavage: the p2/NC site was
decelerated and the CA/p2 site was accelerated. Tritch et al.
(58) had previously noted the importance of context in influ-
encing the rate when they observed that placement of the
p2/NC cleavage site sequence at the MA/CA site resulted in
cleavage that was an order of magnitude slower than the rate
of cleavage in its normal context. The CA/p2 site of Gag may
not be the only site influenced by dynamic changes in context
or conformation. Sheng et al. have also noted that cleavage at
the pl/NC site is influenced by the presence of RNA (50).
We also observed that processing sites differ in allowed
amino acid substitutions. Leu substitutions reduced the rate of
cleavage at the MA/CA junction more than the p2/NC site.
This is in agreement with the suggestion of Partin et al. (38)
that the MA/CA site may be more sensitive to mutation than
other processing sites. The differential effects of the P1 Leu
substitutions may reflect differences in amino acid preferences
that have been noted for the aromatic/Pro and hydrophobic/
hydrophobic classes of sites, of which these two sites are
representative (15, 42).
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